Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814
October 21, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Daniel Crawford
Re: | Request for Acceleration of Effectiveness of |
Registration Statement on Form S-3 (File No. 333-267933)
Dear Mr. Crawford:
Northwest Biotherapeutics, Inc., a Delaware corporation (the “Company”), respectfully requests pursuant to Rule 461 under the Securities Act of 1933, as amended, that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-267933) (the “Registration Statement”) be accelerated and that it be declared effective October 25, 2022 at 4:00 p.m. Eastern time, or as soon as practicable thereafter, unless we or our outside counsel, Gibson, Dunn & Crutcher LLP, request by telephone that such Registration Statement be declared effective at some other time.
Please direct any questions regarding this filing to Brian Lane of Gibson, Dunn & Crutcher LLP at (202) 887-3646.
Very truly yours,
/s/ Linda F. Powers
Linda F. Powers
Chief Executive Officer of Northwest Biotherapeutics, Inc.
cc: Brian Lane, Gibson, Dunn & Crutcher LLP